Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BBIO BridgeBio Pharma	$43.71 +2.0%	$37.93	$21.72 ▼ $45.48	$8.35B	1.15	2.50 million shs	2.46 million shs
BEAM Beam Therapeutics	$20.02 +0.7%	$17.64	$13.53 ▼ $35.25	$2.01B	2.07	1.51 million shs	1.36 million shs
RVMD Revolution Medicines	$37.00 -0.5%	$39.54	$29.17 ▼ $62.40	$7.05B	1.06	1.67 million shs	1.11 million shs
TGTX TG Therapeutics	$37.20 +2.5%	$36.77	$16.65 ▼ $46.48	$5.83B	1.91	2.91 million shs	681,323 shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BBIO BridgeBio Pharma	0.00%	-2.57%	+14.95%	+39.32%	+74.82%
BEAM Beam Therapeutics	0.00%	+19.17%	+16.73%	+31.11%	-14.74%
RVMD Revolution Medicines	0.00%	+0.24%	-8.37%	+18.14%	+0.22%
TGTX TG Therapeutics	0.00%	+1.31%	+0.46%	-0.40%	+97.98%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BBIO BridgeBio Pharma	4.7053 of 5 stars	4.5	2.0	3.9	2.4	3.3	0.6
BEAM Beam Therapeutics	2.5339 of 5 stars	3.5	1.0	0.0	2.6	2.5	0.6
RVMD Revolution Medicines	4.5805 of 5 stars	4.5	2.0	4.7	3.3	1.7	0.0
TGTX TG Therapeutics	3.3067 of 5 stars	1.4	1.0	3.5	2.7	2.5	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BBIO BridgeBio Pharma	2.93	Moderate Buy	$58.85	34.64% Upside
BEAM Beam Therapeutics	3.00	Buy	$48.75	143.51% Upside
RVMD Revolution Medicines	3.00	Buy	$67.58	82.66% Upside
TGTX TG Therapeutics	2.80	Moderate Buy	$40.80	9.68% Upside

Current Analyst Ratings Breakdown

Latest BEAM, TGTX, BBIO, and RVMD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/30/2025	BBIO BridgeBio Pharma	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$67.00 ➝ $76.00
6/25/2025	BBIO BridgeBio Pharma	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$50.00 ➝ $54.00
6/25/2025	RVMD Revolution Medicines	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00
6/24/2025	RVMD Revolution Medicines	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$67.00 ➝ $73.00
6/24/2025	RVMD Revolution Medicines	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$57.00
6/17/2025	BBIO BridgeBio Pharma	Wolfe Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$49.00
6/9/2025	BBIO BridgeBio Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$53.00 ➝ $56.00
5/14/2025	RVMD Revolution Medicines	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$73.00 ➝ $72.00
5/8/2025	RVMD Revolution Medicines	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$67.00
5/8/2025	RVMD Revolution Medicines	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$70.00 ➝ $75.00
5/8/2025	RVMD Revolution Medicines	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$87.00 ➝ $80.00

(Data available from 7/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BBIO BridgeBio Pharma	$221.90M	37.40	N/A	N/A	($7.71) per share	-5.67
BEAM Beam Therapeutics	$63.52M	31.69	N/A	N/A	$8.86 per share	2.26
RVMD Revolution Medicines	$11.58M	595.16	N/A	N/A	$13.47 per share	2.75
TGTX TG Therapeutics	$329M	17.95	$0.12 per share	306.10	$1.43 per share	26.01

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BBIO BridgeBio Pharma	-$535.76M	-$3.53	N/A	N/A	N/A	-524.25%	N/A	-94.43%	7/30/2025 (Estimated)
BEAM Beam Therapeutics	-$376.74M	-$4.61	N/A	N/A	N/A	-609.24%	-44.24%	-30.97%	8/5/2025 (Estimated)
RVMD Revolution Medicines	-$600.09M	-$4.00	N/A	N/A	N/A	N/A	-37.06%	-32.84%	8/6/2025 (Estimated)
TGTX TG Therapeutics	$23.38M	$0.24	155.00	37.20	N/A	10.13%	18.88%	7.05%	8/5/2025 (Estimated)

Latest BEAM, TGTX, BBIO, and RVMD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/7/2025	Q1 2025	RVMD Revolution Medicines	-$1.12	-$1.13	-$0.01	-$1.13	N/A	N/A
5/7/2025	Q1 2025	TGTX TG Therapeutics	$0.19	$0.03	-$0.16	$0.03	$117.07 million	$120.86 million
5/6/2025	Q1 2025	BEAM Beam Therapeutics	-$1.11	-$1.24	-$0.13	-$1.24	$14.69 million	$7.47 million
4/29/2025	Q1 2025	BBIO BridgeBio Pharma	-$1.00	-$0.88	+$0.12	-$0.88	$57.14 million	$36.74 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BBIO BridgeBio Pharma	N/A	N/A	N/A	N/A	N/A
BEAM Beam Therapeutics	N/A	N/A	N/A	N/A	N/A
RVMD Revolution Medicines	N/A	N/A	N/A	N/A	N/A
TGTX TG Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BBIO BridgeBio Pharma	N/A	4.57	4.54
BEAM Beam Therapeutics	N/A	8.81	8.81
RVMD Revolution Medicines	N/A	13.46	13.46
TGTX TG Therapeutics	1.03	4.02	3.04

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BBIO BridgeBio Pharma	99.85%
BEAM Beam Therapeutics	99.68%
RVMD Revolution Medicines	94.34%
TGTX TG Therapeutics	58.58%

Insider Ownership

Company	Insider Ownership
BBIO BridgeBio Pharma	18.20%
BEAM Beam Therapeutics	3.50%
RVMD Revolution Medicines	8.20%
TGTX TG Therapeutics	10.64%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BBIO BridgeBio Pharma	400	189.88 million	155.32 million	Optionable
BEAM Beam Therapeutics	510	100.56 million	97.04 million	Optionable
RVMD Revolution Medicines	250	186.27 million	170.99 million	Optionable
TGTX TG Therapeutics	290	158.76 million	141.86 million	Optionable

BEAM, TGTX, BBIO, and RVMD Headlines

Recent News About These Companies

Braun Stacey Associates Inc. Has $19.82 Million Stock Position in TG Therapeutics, Inc. (NASDAQ:TGTX)

July 5 at 8:41 AM | marketbeat.com

TG Therapeutics, Inc. (TGTX) - Yahoo Finance

July 3 at 5:24 PM | finance.yahoo.com

Jim Cramer on TG Therapeutics: “You Should Buy the Stock”

July 2 at 12:19 PM | insidermonkey.com

Kymera Therapeutics Shows Market Leadership With Jump To 93 RS Rating

July 2 at 11:25 AM | msn.com

Cramer's Lightning Round: TG Therapeutics is a buy

June 30, 2025 | nbcnewyork.comN

TG Therapeutics, Inc. (NASDAQ:TGTX) Shares Sold by Illinois Municipal Retirement Fund

June 30, 2025 | marketbeat.com

TGTX - TG Therapeutics Inc Financials - Morningstar

June 28, 2025 | morningstar.comM

TG Therapeutics: Strong Execution Tempered By An Evolving Market

June 28, 2025 | seekingalpha.com

Spire Wealth Management Acquires 22,750 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX)

June 28, 2025 | marketbeat.com

TGTX - TG Therapeutics Inc Valuation - Morningstar

June 27, 2025 | morningstar.comM

Stocks With Rising Relative Strength: CRISPR Therapeutics

June 26, 2025 | msn.com

TGTX TG Therapeutics, Inc. - Seeking Alpha

June 26, 2025 | seekingalpha.com

TG Therapeutics: Another Possible Avenue Of MS Growth With Azer-Cel

June 25, 2025 | seekingalpha.com

Assenagon Asset Management S.A. Cuts Stake in TG Therapeutics, Inc. (NASDAQ:TGTX)

June 20, 2025 | marketbeat.com

Insider Selling: Yann Echelard Unloads $369K Of TG Therapeutics Stock

June 17, 2025 | benzinga.com

Are Options Traders Betting on a Big Move in TG Therapeutics Stock?

June 17, 2025 | msn.com

Yann Echelard Sells 10,000 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX) Stock

June 17, 2025 | insidertrades.com

Insider Selling: TG Therapeutics, Inc. (NASDAQ:TGTX) Director Sells 10,000 Shares of Stock

June 16, 2025 | marketbeat.com

Cantor Fitzgerald Estimates TG Therapeutics FY2026 Earnings

June 10, 2025 | marketbeat.com

GAMMA Investing LLC Purchases 176,573 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX)

June 9, 2025 | marketbeat.com

TG Therapeutics (NasdaqCM:TGTX) Stock Rises 13% In Last Month

June 7, 2025 | uk.finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BEAM, TGTX, BBIO, and RVMD Company Descriptions

BridgeBio Pharma NASDAQ:BBIO

$43.70 +0.88 (+2.04%)

Closing price 07/3/2025 03:50 PM Eastern

Extended Trading

$43.12 -0.59 (-1.34%)

As of 07/3/2025 04:20 PM Eastern

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.

Beam Therapeutics NASDAQ:BEAM

$20.02 +0.14 (+0.70%)

Closing price 07/3/2025 03:12 PM Eastern

Extended Trading

$20.19 +0.17 (+0.84%)

As of 07/3/2025 04:55 PM Eastern

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

Revolution Medicines NASDAQ:RVMD

$37.00 -0.19 (-0.51%)

Closing price 07/3/2025 03:57 PM Eastern

Extended Trading

$37.39 +0.39 (+1.05%)

As of 07/3/2025 04:56 PM Eastern

Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies. Its RAS(ON) inhibitors include RMC-6236 (multi), RMC-6291 (G12C), and RMC-9805 (G12D), which are in phase 1 clinical trial; and development candidates comprise RMC-5127 (G12V), RMC-0708 (Q61H), and RMC-8839 (G13C), as well as programs focused on G12R and other targets. The company's RAS companion inhibitors include RMC-4630 that is in phase 2 clinical trial; and RMC-5552, which is in phase 1 clinical trial. Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.

TG Therapeutics NASDAQ:TGTX

$37.20 +0.91 (+2.51%)

Closing price 07/3/2025 03:25 PM Eastern

Extended Trading

$36.94 -0.26 (-0.69%)

As of 07/3/2025 04:42 PM Eastern

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time